<img src="https://ml.globenewswire.com/Resource/Download/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b?size=2" nborder="0" align="left" hspace="5" vspace="5" title="ApogeeLogo.png" alt="Apogee Therapeutics"/>Webcast to be held Wednesday, May 27th at 8:00 a.m. ETSAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Apogee Therapeutics’ live webcast of the Phase 2 APEX Part B results will begin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed via this <a href="https://www.globenewswire.com/Tracker?data=VcD2nckL7oyIPX4dM-Rz3FAmtSY-GjLkMm7qSYPqBVpaF4IadF_YbF8nKJowjsNYm_O4C_zPQ8sZ77vo7JWh-1gZEIqOlNiuW4XF3OLyMmU=" rel="nofollow" target="_blank" title="link">link</a> or the Investors section on the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=ZxBwYIhKJCFlPIJx9jW7n0VIZIm7qq_HzS4OmIs07JBEvPsFbMsd-SIEXCR3DNerXFDPfFypkzbF7Ig5O5TBChPZr7GmNLB9BuijMyxL2jrzFpFxzvLC5eWU8r7N2gv8FbBNkKuiDiY3wGVoHPgeGCkECz3hx_7YAmtAr7B9LnsZ6hnaGw0TUPRuehfSSiBY_oOPdqFgHJ-SgMlj1dkv2Zo3ehv1YAHYWRcXvlW5npeOqzNRB6YYnVg1mbWTjoI28aGYLo8rZc1i09HstIn8G8iMJwvoauuw53OHx58fX5vzIKvS0qHDndynfC0z9322T2bWIm4esMeCS2FClALA176Iu7qPcfADq8kwhc6LzcuojMj_wjOUBIAvrjbp__ve_WE3rFw_ZAHaPXPOzgoFyqvSp_gaS06BqOx4ahRj5Ps-PPjDmoAQmlqstiqw8JpKG6TzokbDRM8SxSOOMI4USC70NkfFLX90ydAUo0FLBJCB1I22v8aZTUUkKh5iiiggvfDiOYnSemOdG-VxlcfVlAG-_KEs3ac96SjraSgwE00=" rel="nofollow" target="_blank" title="">https://investors.apogeetherapeutics.com/news-events/events</a>. A replay of the webcast will be available following the call. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&amp;I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&amp;I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&amp;I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=ZxBwYIhKJCFlPIJx9jW7n-aNUBruaGi0JYK0LkbMfBAwHXKt7Hi6ZPpI5INVqlR_A2zBhlz7JI-D9LY5u8s9zCaCCuShK8nzSZ_U6I4Vrs0Ni-JyhDQztLUB6D1KDuHJGYK5ScCzAvNBWTbdKQdEr1xeDuOoHmOyg4CKrZh4Y37WSeCiutgN3b2D6GxBHibFI95vJb75tyTmp50D3aNMU5uYCqIyI-Ilcl0rYp2ikJwjNt_D_76DMVlM6OZUNgGwIBIZl8wH47l8F-1MUbBTQtMJQzScDcuWRJS709WX5adbRwolxbneK9vuvLkm1qj6srxGoBSS8min28njscwnz1u4pMs7_CtMHYfURH6mGi1lGXt1i03tBAESPh3Z1I2-ZAj02PZ9_qKbvpYb7PEIWlbu2Ofeh7PWNBIN3C_85arvdkrfFzYHovhU8TotUz8MhMF2fScVABYhD8bD0I2KLw==" rel="nofollow" target="_blank" title="">https://apogeetherapeutics.com</a>. Investor Contact: Noel Kurdi VP, Investor Relations Apogee Therapeutics, Inc. <a href="https://www.globenewswire.com/Tracker?data=Ri8_CrAdGkNJl0KWtl9w6TrRsEyusmaoUgfF1qVrWwkONJd4afPfED2zWOLQPHedA9hRBgUOkV5wSCkuBTIpPn35PwEW-jZoR69xACJrqRx6G6tPAOIdhJs2DExF9A--Sdmdv04SPIpW-1Bo0ZKcsA==" rel="nofollow" target="_blank" title="">Noel.Kurdi@apogeetherapeutics.com</a> Media Contact: Dan Budwick 1AB Media <a href="https://www.globenewswire.com/Tracker?data=9FC37JFF0-Hb2hvCT_m-6np6VeZk8CLAm7OlcMvRkHFXYFNQ2AKmdaSvhYsF-wSsgAm-Ys68WzDjCg_V1i9bwsnKamE1MymIQDlAlPsr4YA=" rel="nofollow" target="_blank" title="">dan@1abmedia.com</a> <img alt="" src='https://ml.globenewswire.com/media/OWQyYTM5MzctYmM2OS00ZGEzLWI2MTQtNDJjMmRkZTlhNWM3LTEyNzA3NzctMjAyNi0wNS0yNi1lbg==/tiny/Apogee-Therapeutics.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn